Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common equivalent shares of the Company, including outstanding stock options, RSUs, and warrants to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common equivalent shares of the Company outstanding would have been anti-dilutive.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock:


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Numerator:
Net Loss	$	(9,298	)	$	(9,225	)	$	(17,921	)	$	(18,643	)
Numerator for Basic and Dilutive EPS – Loss available to common stockholders	$	(9,298	)	$	(9,225	)	$	(17,921	)	$	(18,643	)
Denominator:
Common Stock		99,797,156			78,077,118			98,751,951			76,893,733
Denominator for Basic and Dilutive EPS - Weighted-average common stock		99,797,156			78,077,118			98,751,951			76,893,733
Basic and dilutive net loss per share	$	(0.09	)	$	(0.12	)	$	(0.18	)	$	(0.24	)

Since the Company was in a net loss position for all periods presented, net loss per share attributable to Class A and Class B common stockholders was the same on a basic and diluted basis, as the inclusion of all common equivalent shares outstanding would have been anti-dilutive. Anti-dilutive common equivalent shares were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Outstanding options to purchase common stock		15,688,709		17,016,565		15,688,709		17,016,565
Outstanding RSUs		5,921,884		2,567,691		5,921,884		2,567,691
Warrants issued in connection with February 2025 Offering		4,257,419		4,511,178		4,257,419		4,511,178
Warrants issued in connection with Loan Agreement		562,500		—		562,500		—
Total anti-dilutive common equivalent shares		26,430,512		24,095,434		26,430,512		24,095,434

The Loan Agreement also provides for Additional Warrants to purchase up to an aggregate of 520,835 shares of Class A common stock, contingent on and exercisable only upon the funding of future term loan tranches under the Loan Agreement. As no additional term loan tranches had been drawn as of June 30, 2026, no shares were issuable under the Additional Warrants as of June 30, 2026, and such Additional Warrants were excluded from the table above.